SCHEMBL1947

SCHEMBL1947

CCCC[Si](C)(CCCC)CCOC=O

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11217194 0.83 TSHR (0.31) TSHR
Butyl Formate SCHEMBL5847 0.74
Butyl Formate SCHEMBL29688477 0.74 ATM (0.42) TSHR
SCHEMBL3676139 0.74 TSHR (0.43) TSHR
Butyl Formate SCHEMBL6599284 0.72
Butyl Formate SCHEMBL28045685 0.72
Butyl Formate SCHEMBL28320458 0.72
Butyl Formate SCHEMBL3206729 0.72
SCHEMBL28169 0.72
Butyl Formate SCHEMBL27029705 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0362634-A2 Basic dihydropyridines, process for their preparation and their use as intermediates BAYER AG (DE) 1990-04-11 EP claimed
EP-2464623-B1 THE RING OPENING OF LACTONES AND LACTAMS NOVARTIS AG (CH) 2020-11-04 EP disclosed
US-8779198-B2 Ring opening of lactones and lactams NOVARTIS AG (CH) 2014-07-15 US disclosed
US-8507673-B2 Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds EMORY UNIVERSITY (US) 2013-08-13 US disclosed
US-20120165555-A1 RING OPENING OF LACTONES AND LACTAMS NOVARTIS AG (CH) 2012-06-28 US disclosed
EP-2464623-A1 THE RING OPENING OF LACTONES AND LACTAMS Novartis AG (CH) 2012-06-20 EP disclosed
US-20120041198-A1 Process for Preparing 5,7 Diaminopyrazolo [1,5-a] Pyrimidine Compounds EMORY UNIVERSITY 2012-02-16 US disclosed
US-8034810-B2 Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting NOVARTIS AG (CH) 2011-10-11 US disclosed
WO-2011019789-A1 THE RING OPENING OF LACTONES AND LACTAMS NOVARTIS AG (CH) 2011-02-17 WO disclosed
US-20100298328-A1 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes VITAE PHARMACEUTICALS, INC 2010-11-25 US disclosed
US-4313945-A 7-Thiazolyl-acetamido-cephem derivatives with terminal aminocarboxylic acid grouping CIBA-GEIGY CORPORATION (US) 1982-02-02 US disclosed
EP-0041047-A2 Dioxide compounds, process for their preparation and their use CIBA-GEIGY AG (CH) 1981-12-02 EP disclosed
EP-0037797-A2 Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application CIBA-GEIGY AG (CH) 1981-10-14 EP disclosed
EP-0034347-A2 Derivatives of aldohexoses, intermediates, process for their production, preparations containing such compositions and their use CIBA-GEIGY AG (CH) 1981-08-26 EP disclosed
EP-0031794-A2 Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1981-07-08 EP disclosed
EP-0023885-A1 Method for the introduction of an oxygen-containing functional group into ansamycines, compounds thus obtained, and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1981-02-11 EP disclosed
EP-0022245-A2 Aminothiadiazolyl derivatives, process for their preparation, pharmaceutical compositions containing them;starting compounds and process for their preparation CIBA-GEIGY AG (CH) 1981-01-14 EP disclosed
EP-0016296-A1 Cephalosporin derivatives, process for their preparation, compositions containing them, and intermediates and their preparation CIBA-GEIGY AG (CH) 1980-10-01 EP disclosed
EP-0015240-A1 Azacyclyl (thio) ureidoacetyl compounds and their preparation CIBA-GEIGY AG (CH) 1980-09-03 EP disclosed
EP-0009008-A2 Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1980-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298328-A1 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes REN, AGTR1, AGTR2 TSHR 3735/4885
US-20120041198-A1 Process for Preparing 5,7 Diaminopyrazolo [1,5-a] Pyrimidine Compounds DPYD, NUDT1, UMPS TSHR 3560/4885
US-20120165555-A1 RING OPENING OF LACTONES AND LACTAMS LSS, APH1A, OTUB1 TSHR 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.